News
Novo Nordisk announces CEO transition as share price slips
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release announcing the leadership shake up. Jorgensen will stay on as CEO temporarily for an undetermined period of time “to support a smooth transition” as the company looks for his replacement.
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
In an abrupt and surprising twist, the CEO of Ozempic-maker Novo Nordisk has been ousted from his position as the head of the ...
As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback